Drug Trial Radar · NCT02522650
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria
Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 2013
Primary completion
Oct 2021
Study completion Oct 2021
Sponsor
- Lead sponsor
- Georgetown UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This cross-over study is designed to test the hypothesis that amiloride will reduce urinary protein excretion and protect the kidney from rapid progression in proteinuric kidney disease.
Conditions
- Proteinuria
Interventions
AmilorideDrug
5mg twice a day for 8 weeks
TriamtereneDrug
50mg twice a day for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24 hr urine protein excretionTime frame: 20 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Georgetown University
Washington D.C., District of Columbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.